Core Viewpoint - Fermi Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding its Project Matador campus and tenant commitments, with a deadline for investors to seek lead plaintiff status set for March 6, 2026 [1] Company Overview - Fermi Inc. (NASDAQ: FRMI) completed its IPO on October 1, 2025, offering approximately 32.5 million shares at $21.00 per share [1] - The company aimed to develop a large electric generation campus for AI data centers and had identified a "First Tenant" for its Project Matador site [1] Allegations and Legal Proceedings - The lawsuit claims that Fermi and its executives violated federal securities laws by making false or misleading statements, including: 1. Overstating tenant demand for Project Matador [1] 2. Failing to disclose reliance on a single tenant's funding commitment [1] 3. Not revealing the risk of the tenant terminating its funding commitment [1] 4. Misleading statements about the company's business and prospects [1] - The First Tenant had agreed to advance up to $150 million for construction costs but terminated this agreement on December 12, 2025, leading to a significant drop in Fermi's stock price by over 33% to $10.09 per share [1] Investor Information - Investors who purchased Fermi securities during the class period (October 1, 2025, to December 11, 2025) are encouraged to contact Faruqi & Faruqi, LLP for legal options [1] - The firm has a history of recovering hundreds of millions for investors since its founding in 1995 [1]

Core Viewpoint - A class action lawsuit has been filed against uniQURE N.V. on behalf of investors who acquired its securities during the specified class period from September 24, 2025, to October 31, 2025 [1] Group 1 - The law firm Kirby McInerney LLP is representing the investors in the class action lawsuit [1] - Investors who suffered losses on their uniQURE investments have until April 13, 2026, to request lead plaintiff appointment [1] - Courts do not consider lead plaintiff applications submitted after the deadline [1]

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against KDDI Corporation, focusing on possible violations of federal securities laws by the company and its senior management [1] Group 1: Investigation Details - The investigation was prompted by KDDI's announcement on February 6, 2026, regarding the postponement of its earnings report for the third quarter of the fiscal year ending March 2026, citing uncertainties related to quarterly results and an internal investigation [1] - Following the announcement, KDDI's share price fell by $2.03, or approximately 11.44%, from $17.74 on February 5, 2026, to close at $15.71 on February 6, 2026 [1] Group 2: Legal Context - No lawsuit has been filed yet, and the investigation is ongoing to determine if claims can be brought under federal securities laws [1] - Investors who purchased or acquired KDDI securities are encouraged to contact Kirby McInerney LLP for more information regarding their rights or interests related to the investigation [1]

Core Thesis - Merck & Co., Inc. (MRK) is experiencing a bullish sentiment driven by significant institutional options trading and upcoming catalysts, suggesting a medium-term price increase [2][3][5]. Institutional Activity - On December 8, 2025, a large institutional trade involved the purchase of 30,000 April 17, 2026 $110 call contracts, amounting to approximately $300 million in notional exposure, indicating a strategic bet on MRK's price movement [2]. Strategic Options Positioning - The proposed strategy includes a split-strike risk reversal, selling April $85 puts to finance the $110 calls, which aims to limit downside risk while positioning for potential upside [3]. Fundamental Drivers - Key growth drivers include the launch of Winrevair, which is on track for blockbuster status, the sustained performance of the Keytruda franchise, and a robust pipeline with promising developments in cardiology, vaccines, and respiratory diseases [4]. Market Context - Merck is trading at a valuation discount within the healthcare sector, coupled with a strong dividend yield that provides a safety net, making it an attractive investment during a macro rotation into healthcare defensives [5]. Historical Performance - Since a previous bullish thesis in April 2025, MRK's stock price has increased by approximately 30.50%, attributed to improving margins and strong free cash flow generation [6].

Performance Summary - Apis Flagship Fund achieved a net return of 10.0% in Q4 2025 and a total gain of 55.1% for the year, outperforming the MSCI ACWI benchmark by approximately 7.0% in Q4 and 33.0% for the year [1] - Long positions contributed 11.9% gross to the fund's performance, while short positions added 0.8% gross, with a net long position of around 68% as of December [1] - The performance was broad-based, with Technology and Healthcare sectors leading returns, and basic materials also contributing significantly [1] Stock Highlights - uniQure (NASDAQ:QURE) is a gene therapy company focused on rare and neurological diseases, with a one-month return of 0.44% and a market capitalization of approximately $1.4 billion as of January 30, 2026 [2] - The stock traded between $7.76 and $71.50 over the last 52 weeks, closing at about $22.72 per share [2] Key Contributors and Detractors - Celcuity was the top contributor in Q4, adding 3.8% during the quarter and 4.4% for the full year [3] - Memory semiconductor companies contributed over 5.0% to returns, with Kioxia Holdings being a notable performer [3] - uniQure detracted about 1.1% from performance, while Korean defense-related holdings collectively detracted approximately 2.5% in Q4 [3] - The weakness in uniQure and Korean holdings was attributed to a technical pause rather than a decline in fundamentals [3] - Hyundai Rotem, Poongsan, and Hanwha Aerospace were among the top contributors for the year, collectively adding over 11.0% to annual performance [3]

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a promising investment opportunity with significant upside potential, supported by recent positive financial results and analyst upgrades [1][2][3]. Financial Performance - Soleno Therapeutics announced preliminary unaudited full-year 2025 net revenue for its VYKAT XR offering, exceeding estimates by $16.5 million to $18.5 million [2] - The anticipated preliminary fourth-quarter 2025 net revenue is projected to be between $90 million and $92 million, significantly higher than the analyst guidance of $73.8 million [2]. Analyst Ratings and Price Targets - H.C. Wainwright raised the price target for Soleno Therapeutics to $120 from $110, indicating an upside potential of 177% [1] - Wells Fargo also increased its price target to $114 from $106 and maintained an Overweight rating, citing the strong fourth-quarter revenue performance [3]. Company Overview - Soleno Therapeutics is a California-based clinical-stage biopharmaceutical company founded in 1999, specializing in novel therapeutics for serious illnesses, including Diazoxide Choline Extended-Release tablets [4].

Core Insights - The Alger Small Cap Focus Fund's fourth-quarter 2025 investor letter highlights a strong performance in the US equity market, with the S&P 500 increasing by 2.7% due to better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The letter notes a divergence in market performance, particularly regarding AI investments, which face skepticism due to various challenges [1] - The Fund's Class A shares outperformed the Russell 2000 Growth Index, with contributions from the Utilities and Financials sectors, while Consumer Discretionary and Information Technology sectors negatively impacted performance [1] Company Insights - UniQure N.V. (NASDAQ:QURE) is a biotechnology company focused on developing treatments for rare diseases, specifically AMT-130 for Huntington's disease, which currently lacks approved disease-modifying treatments [2][3] - The stock of UniQure N.V. experienced a one-month return of -8.57% but gained 62.56% over the past 52 weeks, closing at $22.84 with a market capitalization of $1.42 billion on November 18, 2025 [2] - The company's shares were volatile in 2025, initially surging after promising Phase 1/2 data but later facing regulatory uncertainty due to FDA feedback regarding the adequacy of external-control data for accelerated approval [3]

Group 1 - UniQure (NASDAQ:QURE) is considered a promising stock to buy under $50, with recent price target adjustments from analysts [1][2] - Stifel lowered its price target for UniQure to $40 from $50 while maintaining a Buy rating, following a comprehensive review of the biotech sector [1] - Mizuho reduced its price target for UniQure to $33 from $60, maintaining an Outperform rating, due to regulatory concerns regarding the Phase I/II studies for AMT-130 [2][3] Group 2 - The FDA indicated that current data for AMT-130 likely lacks the primary evidence required for a Biologics License Application (BLA), leading to a reduced probability of success and a delayed market launch by one year [2][3] - Despite these challenges, there is optimism about AMT-130's long-term potential, with a follow-up Type A meeting with the FDA scheduled for Q1 2026 to establish a new path forward [3]

Group 1 - UniQure (NASDAQ:QURE) is considered a promising small-cap stock with significant upside potential, despite recent price target reductions by analysts [1][2] - Stifel reduced its price target for UniQure from $50 to $40 while maintaining a Buy rating, citing refreshed diligence on biotechnology companies [1] - Mizuho analyst Uy Ear lowered the price target from $60 to $33 but kept an Outperform rating, indicating a decreased probability of success for the company's AMT-130 therapy [2] Group 2 - UniQure announced on December 4 that it received final meeting minutes from the FDA regarding the pre-Biologics License Application (BLA) meeting for AMT-130, an investigational gene therapy for Huntington's disease [3] - The FDA indicated that the data from Phase I/II studies of AMT-130 is unlikely to support a BLA submission, prompting UniQure to plan a follow-up meeting with the FDA for fiscal Q1 2026 [4] - UniQure focuses on developing innovative gene therapies for conditions such as Huntington's disease, hemophilia, and cardiovascular issues [5]

Group 1: Toro Co Performance - Toro Co reported quarterly earnings of 91 cents per share, exceeding the analyst consensus estimate of 87 cents per share [1] - The company achieved quarterly sales of $1.066 billion, surpassing the analyst consensus estimate of $1.048 billion [1] - Following the earnings report, Toro's shares rose by 7% to $77.82 [1] Group 2: Other Notable Stock Movements - DBV Technologies SA shares increased by 35.5% to $24.36 after meeting primary endpoints in the Phase 3 VITESSE trial [3] - Udemy Inc gained 26.5% to $6.79 due to an all-stock merger agreement with Coursera [3] - Kodiak Sciences Inc jumped 16.7% to $28.16 after announcing a public offering of common stock [3] - Hut 8 Corp rose 16.3% to $42.88 following a partnership to accelerate AI infrastructure deployment and a $7.0 billion lease agreement [3] - Canopy Growth Corp increased by 16.2% to $2.13 amid reports of potential reclassification of marijuana [3] - Recursion Pharmaceuticals Inc gained 13.2% to $4.76 after an upgrade from JP Morgan [3] - Two Harbors Investment Corp surged 13.2% to $11.21 due to an acquisition announcement [3] - Quantumscape Corp gained 7.7% to $11.66 after signing a joint development agreement with a top-10 global automaker [3] - Jabil Inc reported better-than-expected earnings, leading to a 7% increase in shares to $227.50 [3]